Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab combinations in advanced Non-Small Cell Lung Cancer
NCT02750514Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- May 2016
- Primary completion
- Jan 2020
- Modality
- Fragment-Derived Small Molecules, Immune Checkpoint Inhibitors, Allosteric Modulators
- Countries
- 8
01
Overview
A Phase 2 trial of dasatinib, relatlimab, ipilimumab, linrodostat in non-small cell lung cancer (NSCLC), sponsored by Bristol Myers Squibb. Started May 2016; status: terminated.
02
Drugs
dasatinibrelatlimabipilimumablinrodostat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02750514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02750514.